We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+139.21%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.3B
AUM Growth
+$1.62B
Cap. Flow
+$431M
Cap. Flow %
13.06%
Top 10 Hldgs %
71.48%
Holding
41
New
9
Increased
7
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$91.7M
2
ETNB
89bio
ETNB
+$88M
3
ARVN icon
Arvinas
ARVN
+$58.8M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$56.2M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$44.4M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$35.3M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$32.1M
3
DTIL icon
Precision BioSciences
DTIL
+$15.5M
4
KOD icon
Kodiak Sciences
KOD
+$14.7M
5
AXSM icon
Axsome Therapeutics
AXSM
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 95.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
26
Solid Biosciences
SLDB
$792M
$20.3M 0.62%
304,744
– –
SCPH
27
DELISTED
scPharmaceuticals
SCPH
$18.4M 0.56%
3,247,005
– –
ALEC icon
28
Alector
ALEC
$169M
$17.2M 0.52%
1,000,000
– –
KALA icon
29
KALA BIO
KALA
$12.5M
$16.7M 0.51%
1,817
– –
GRTX
30
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$13.9M 0.42%
+1,054,178
New +$12.9M
DVAX
31
DELISTED
Dynavax Technologies
DVAX
$13.5M 0.41%
2,365,912
– –
PTLA
32
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$10.3M 0.31%
429,399
– –
EPIX
33
DELISTED
ESSA Pharma
EPIX
$5.5M 0.17%
1,000,000
– –
XFOR icon
34
X4 Pharmaceuticals
XFOR
$377M
$2.89M 0.09%
9,010
-6,927
-43% -$2.48M
DTIL icon
35
Precision BioSciences
DTIL
$178M
– –
-61,412
Closed -$15.5M
KOD icon
36
Kodiak Sciences
KOD
$2.5B
– –
-1,025,165
Closed -$14.7M
SENS icon
37
Senseonics Holdings Inc
SENS
$254M
– –
-136,364
Closed -$2.7M
CMRX
38
DELISTED
Chimerix, Inc.
CMRX
– –
-1,782,202
Closed -$4.19M
MYOV
39
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-6,166,875
Closed -$32.1M
ODT
40
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-200,000
Closed -$5.21M
DRNA
41
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-2,456,669
Closed -$35.3M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, RA Capital Management held 41 positions worth $3.3B, up 96% from $1.68B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

RA Capital Management deployed $431M of net new capital in Q4 2019, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $12M trimmed.

  • RA Capital Management's largest Q4 2019 buy was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.
  • RA Capital Management added most to Arvinas in Q4 2019, an estimated $58.8M increase.
  • RA Capital Management's biggest Q4 2019 reduction was Axsome Therapeutics, cutting an estimated $12M.
  • RA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2019, selling an estimated $35.3M.
  • RA Capital Management's ten largest holdings make up 71% of its $3.3B portfolio in Q4 2019.
  • RA Capital Management opened 9 new positions and closed 7 in Q4 2019.
  • RA Capital Management's portfolio value rose 96% quarter-over-quarter to $3.3B.

Based on RA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.